(redirected from P-glycoprotein)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to P-glycoprotein: ABCB1
PGPPretty Good Privacy
PGPPhysician Group Practice (Medicare)
PGPPhysics of Geological Processes
PGPPassword Generator Protocol
PGPPretty Good Protection (encryption)
PGPPearl of Great Price
PGPProgram Parameter (File Name Extension)
PGPProcter & Gamble Productions
PGPPersonal Growth Plan
PGPPfizer Global Pharmaceuticals
PGPPayment Gateway Provider (electronic commerce)
PGPPower Generation Plant (various locations)
PGPPreemptive Goal Programming
PGPPower Generation Platform
PGPPreferred Gender Pronoun (liguistics)
PGPProcedures Generation Package
PGPPast Grand Patriarch (IOOF)
PGPPrivate Generating Plant
PGPFundación Pequeñas Grandes Personas (Little People of Chile)
PGPPrevious Glacial Period
PGPPerforated Ground Plane
PGPProtected Gold Participation Unit
PGPPretty Good Pigeons
PGPParti Gabonaise du Progres (Gabonese Party for Progress)
PGPPost Graduate Programme (India)
PGPP-Glycoprotein (biology)
PGPPro-Gun Progressive (politics)
PGPProcter & Gamble Pharmaceuticals, Inc.
References in periodicals archive ?
Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.
Immunohistochemical identification of P-glycoprotein in previously untreated diffuse large cell and immunoblastic lymphomas.
Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.
21, that an atypical codon may affect the pace at which cells assemble P-glycoprotein.
The azoles can interact through multiple mechanisms, including CYP450 metabolism, gastric pH-dependent effects, and P-glycoprotein activity.
Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein.
The Immunomedics invention involves the use of at least two antibodies fused together to result in a bispecific molecule to target both the cancer cells (or infectious organisms) and a multi-drug transporter protein such as P-glycoprotein.
In vitro and in vivo evaluation of phenylbutenoid dimers as inhibitors of P-glycoprotein.
1]] The recommended dose of Lixiana is 60 mg once-daily, with a dose reduction to 30 mg once-daily in patients with moderate or severe renal impairment (creatinine clearance[CrCL] 15-50 mL/min), body weight[less than or equal to] 60 kg, or concomitant use of certain P-glycoprotein (P-gp) inhibitors (ciclosporin, dronedarone, erythromycin, ketoconazole, quinidine or verapamil).
About Orascovery The Orascovery program is based on important platform technology initially developed by Hanmi Pharmaceutical, including compound HM30181A, which is a highly potent and selective P-glycoprotein (PGP) pump inhibitor.
Oraxol and Oratecan are two of many compounds that could be developed by Kinex and its partners through the Orascovery program, which is based on a major platform technology developed by Hanmi Pharmaceuticals using compound HM30181A, a potent and selective P-glycoprotein (PGP) pump inhibitor.
P-glycoprotein belongs to the ATP-binding cassette superfamily of transporters and is a product of the multidrug-resistant gene (61).